Muscle and fat composition in patients with newly diagnosed multiple myeloma

被引:4
|
作者
Abdallah, Nadine H. [1 ]
Nagayama, Hiroki [2 ]
Takahashi, Naoki [2 ]
Gonsalves, Wilson [1 ]
Fonder, Amie [1 ]
Dispenzieri, Angela [1 ]
Dingli, David [1 ]
Buadi, Francis K. [1 ]
Lacy, Martha Q. [1 ]
Hobbs, Miriam [1 ]
Gertz, Morie A. [1 ]
Binder, Moritz [1 ]
Kapoor, Prashant [1 ]
Warsame, Rahma [1 ]
Hayman, Suzanne R. [1 ]
Kourelis, Taxiarchis [1 ]
Hwa, Yi L. [1 ]
Lin, Yi [1 ]
Kyle, Robert A. [1 ]
Rajkumar, S. Vincent [1 ]
Broski, Stephen M. [2 ]
Kumar, Shaji K. [1 ]
机构
[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA
[2] Mayo Clin, Div Radiol, Rochester, MN USA
关键词
SKELETAL-MUSCLE; BODY-COMPOSITION; COMPUTED-TOMOGRAPHY; PROGNOSTIC-FACTOR; ADIPOSE-TISSUE; SOLID TUMORS; OLDER-ADULTS; SARCOPENIA; ATTENUATION; STRENGTH;
D O I
10.1038/s41408-023-00934-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Measures of muscle and adipose tissue mass have been associated with outcomes in several malignancies, but studies in multiple myeloma (MM) are inconsistent. The aim of this study was to evaluate the association between muscle and fat areas and radiodensity, and overall survival (OS) in patients with newly diagnosed MM. We included 341 patients diagnosed with MM from 2010-2019 who had an 18F-fluorodeoxyglucose positron emission tomography/computed tomography at diagnosis. A cross-sectional image at the third lumbar vertebrae was segmented into muscle and fat components. Median follow up was 5.7 years. There was no association between sarcopenia and baseline disease characteristics or OS. Low muscle radiodensity was associated with higher disease stage, anemia, and renal failure. OS was 5.6 vs. 9.0 years in patients with muscle radiodensity in the lower vs. middle/upper tertiles, respectively (P = 0.02). High subcutaneous adipose tissue (SAT) radiodensity was associated with higher stage, anemia, thrombocytopenia, hypercalcemia, renal failure, and high LDH. OS was 5.4 years vs. not reached in patients with SAT radiodensity in the upper vs. middle/lower tertiles, respectively (P = 0.001). In conclusion, sarcopenia was not associated with OS in MM patients. High SAT radiodensity and low muscle radiodensity were associated with advanced disease stage and adverse laboratory characteristics.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma
    Abdallah, Nadine
    Nagayama, Hiroki
    Takahashi, Naoki
    Gonsalves, Wilson I.
    Fonder, Amie
    Dispenzieri, Angela
    Dingli, David
    Buadi, Francis K.
    Lacy, Martha Q.
    Hobbs, Miriam A.
    Gertz, Morie A.
    Binder, Moritz
    Kapoor, Prashant
    Warsame, Rahma M.
    Hayman, Suzanne R.
    Kourelis, Taxiarchis
    Hwa, Yi L.
    Lin, Yi
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Broski, Stephen
    Kumar, Shaji K.
    [J]. BLOOD, 2022, 140 : 7141 - 7143
  • [2] Muscle and fat composition in patients with newly diagnosed multiple myeloma
    Nadine H. Abdallah
    Hiroki Nagayama
    Naoki Takahashi
    Wilson Gonsalves
    Amie Fonder
    Angela Dispenzieri
    David Dingli
    Francis K. Buadi
    Martha Q. Lacy
    Miriam Hobbs
    Morie A. Gertz
    Moritz Binder
    Prashant Kapoor
    Rahma Warsame
    Suzanne R. Hayman
    Taxiarchis Kourelis
    Yi L. Hwa
    Yi Lin
    Robert A. Kyle
    S. Vincent Rajkumar
    Stephen M. Broski
    Shaji K. Kumar
    [J]. Blood Cancer Journal, 13
  • [3] Alteration of muscle mass after chemotherapy in patients with newly diagnosed multiple myeloma
    Nakamura, S.
    Miki, H.
    Okamoto, Y.
    Sogabe, K.
    Oura, M.
    Takahashi, M.
    Iwasa, M.
    Harada, T.
    Fujii, S.
    Kagawa, K.
    Abe, M.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [4] Oprozomib in patients with newly diagnosed multiple myeloma
    Hari, Parameswaran
    Matous, Jeffrey V.
    Voorhees, Peter M.
    Shain, Kenneth H.
    Obreja, Mihaela
    Frye, John
    Fujii, Hisaki
    Jakubowiak, Andrzej J.
    Rossi, Davide
    Sonneveld, Pieter
    [J]. BLOOD CANCER JOURNAL, 2019, 9 (9)
  • [5] Oprozomib in patients with newly diagnosed multiple myeloma
    Parameswaran Hari
    Jeffrey V. Matous
    Peter M. Voorhees
    Kenneth H. Shain
    Mihaela Obreja
    John Frye
    Hisaki Fujii
    Andrzej J. Jakubowiak
    Davide Rossi
    Pieter Sonneveld
    [J]. Blood Cancer Journal, 9
  • [6] Management of Newly Diagnosed Elderly Multiple Myeloma Patients
    Crystal Antoine-Pepeljugoski
    Marc Justin Braunstein
    [J]. Current Oncology Reports, 2019, 21
  • [7] Experimental Characteristics of Patients with Newly Diagnosed Multiple Myeloma
    Li, Linzhang
    Han, Chengwu
    Yu, Xueying
    Cai, Ying
    Cao, Yongyue
    Shen, Jun
    Cao, Yongtong
    [J]. ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, 2023, 29 (08) : 529 - 533
  • [8] Peripheral neuropathy in newly diagnosed multiple myeloma patients
    Ballegaard, Martin
    Gimsing, Peter
    [J]. NEUROLOGY, 2008, 70 (11) : A366 - A367
  • [9] Review of 1027 patients with newly diagnosed multiple myeloma
    Kyle, RA
    Gertz, MA
    Witzig, TE
    Lust, JA
    Lacy, MQ
    Dispenzieri, A
    Fonseca, R
    Rajkumar, SV
    Offord, JR
    Larson, DR
    Plevak, ME
    Therneau, TM
    Greipp, PR
    [J]. MAYO CLINIC PROCEEDINGS, 2003, 78 (01) : 21 - 33
  • [10] Management of Newly Diagnosed Elderly Multiple Myeloma Patients
    Antoine-Pepeljugoski, Crystal
    Braunstein, Marc Justin
    [J]. CURRENT ONCOLOGY REPORTS, 2019, 21 (07)